Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization-Reference-Cited by-同舟云学术

Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization

Published:2019-02-04 Issue:7 Volume:46 Page:1506-1517
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Delaunay Kostas,Edeline Julien,Rolland Yan,Lepareur Nicolas,Laffont Sophie,Palard Xavier,Bouvry Christelle,Le Sourd Samuel,Pracht Marc,Ardisson Valérie,Noiret Nicolas,Bellissant Éric,Garin Etienne^ORCID

Funder

Labex IRON

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-019-04277-9/fulltext.html

Reference33 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

3. Vilgrain V, Bouattour M, Sibert A, Lebtahi R, Ronot M, Pageaux G-P, et al. SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. J Hepatol. 2017;66:S85–6.